According to official statistics, China has 110 million diabetic patients, and direct medical expenses from diabetes are said to account for 13 % of the total medical expenses. 3d generation recombinant insulin glargine is the treatment of choice for diabetes-I patients. According to a representative of the Chinese Diabetes Society, clinical trials with glargine from Gan & Lee Biotechnology Co., Beijing, have shown that their product is bioequivalent to imported glargine and on the way to the Chinese market.

China Bio news release, August 18, 2016